Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK translocation

MeSH terms

• Adenocarcinoma / drug therapy*
• Adenocarcinoma / genetics
• Adenocarcinoma / pathology
• Adenocarcinoma of Lung
• Aged
• Antineoplastic Agents / administration & dosage
• Antineoplastic Agents / adverse effects*
• Blindness / chemically induced*
• Brain Neoplasms / complications
• Brain Neoplasms / diagnosis
• Brain Neoplasms / drug therapy*
• Brain Neoplasms / genetics
• Brain Neoplasms / radiotherapy
• Brain Neoplasms / secondary
• Cranial Irradiation
• Crizotinib
• Disease Progression
• Drug Administration Schedule
• Female
• Humans
• Lung Neoplasms / drug therapy*
• Lung Neoplasms / genetics
• Lung Neoplasms / pathology
• Magnetic Resonance Imaging
• Muscle Weakness / etiology
• Oncogene Proteins, Fusion / genetics*
• Optic Nerve Diseases / chemically induced*
• Protein Kinase Inhibitors / administration & dosage
• Protein Kinase Inhibitors / adverse effects*
• Pyrazoles / administration & dosage
• Pyrazoles / adverse effects*
• Pyridines / administration & dosage
• Pyridines / adverse effects*
• Signal Transduction / drug effects
• Translocation, Genetic* / drug effects